Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The Akkermansia Company is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are distributed across 2 distinct art units, suggesting that the company's biological research is being evaluated by different specialized groups at the USPTO. The pending workload is assigned to 2 distinct examiners, ensuring that each matter is reviewed by a different individual.
MOREAU, NASHARA LOUISE is the busiest examiner for the portfolio, currently overseeing 1 pending office action. This specific action represents half of the 2 total pending office actions for the company. With 2 distinct art units involved, the prosecution strategy must account for the differing standards of two separate USPTO divisions. The involvement of 2 distinct examiners means the company must maintain two separate lines of communication to resolve its current pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 66.7% | -80.0% |
| DEVI, SARVAMANGALA | 1 | 65.5% | +55.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684682 | COMPOSITION COMPRISING PASTEURIZED AKKERMANSIA FOR THE TREATMENT OR PREVENTION OF IBS-RELATED ANXIETY | MOREAU, NASHARA LOUISE | 8d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035766 | COMPOSITION COMPRISING AKKERMANSIA MUCINIPHILA AND GREEN TEA EXTRACT | DEVI, SARVAMANGALA | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684682 | COMPOSITION COMPRISING PASTEURIZED AKKERMANSIA FOR THE TREATMENT OR PREVENTION OF IBS-RELATED ANXIETY | MOREAU, NASHARA LOUISE | 1655 | §101§102§103§112 | Non-Final OA | 8d overdue | Pending | Feb 18, 2024 |
| 18035766 | COMPOSITION COMPRISING AKKERMANSIA MUCINIPHILA AND GREEN TEA EXTRACT | DEVI, SARVAMANGALA | 1645 | §103§112DP | Final Rejection | — | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Akkermansia Company has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Nashara Louise Moreau has the most, with 1 of The Akkermansia Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
